학술논문
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Document Type
Journal Article
Author
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine; LUX-Breast 1 study group (CORPORATE AUTHOR)
Source
Subject
*BREAST cancer treatment
*GENETICS of breast cancer
*VINORELBINE
*TRASTUZUMAB
*GENETIC overexpression
*HER2 gene
*RANDOMIZED controlled trials
*THERAPEUTICS
*ANTINEOPLASTIC agents
*BREAST tumors
*CANCER relapse
*CANCER invasiveness
*CELL receptors
*COMBINED modality therapy
*COMPARATIVE studies
*DRUG administration
*DOSE-effect relationship in pharmacology
*HETEROCYCLIC compounds
*MASTECTOMY
*RESEARCH methodology
*MEDICAL cooperation
*METASTASIS
*PROGNOSIS
*RESEARCH
*RISK assessment
*SURVIVAL analysis (Biometry)
*VINBLASTINE
*EVALUATION research
*TREATMENT effectiveness
*PROPORTIONAL hazards models
*KAPLAN-Meier estimator
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1470-2045
Abstract